Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution

[1]  R. Rector,et al.  Chronic NOS inhibition accelerates NAFLD progression in an obese rat model. , 2015, American journal of physiology. Gastrointestinal and liver physiology.

[2]  Fumiko Kimura,et al.  LipoSEARCH®; Analytical GP-HPLC method for lipoprotein profiling and its applications , 2013 .

[3]  P. Scherer,et al.  Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase , 2012, Journal of cellular biochemistry.

[4]  H. Kirikoshi,et al.  Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. , 2012, Cell metabolism.

[5]  F. Itoh,et al.  Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? , 2012, Journal of Gastroenterology.

[6]  Type of Steatosis Influences Microcirculation and Fibrogenesis in Different Rat Strains , 2011, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[7]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[8]  Rational approach to the synthesis, evaluation, and (68)ga labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase. , 2010, Cancer biotherapy & radiopharmaceuticals.

[9]  C T Rubin,et al.  Quantification of adiposity in small rodents using micro-CT. , 2010, Methods.

[10]  Hirokazu Takahashi,et al.  The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease , 2010, Journal of Gastroenterology.

[11]  Hirokazu Takahashi,et al.  Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. , 2009, Journal of hepatology.

[12]  Hirokazu Takahashi,et al.  Dysfunctional very‐low‐density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis , 2009, Hepatology.

[13]  Paul L Huang.  eNOS, metabolic syndrome and cardiovascular disease , 2009, Trends in Endocrinology & Metabolism.

[14]  S. Butz,et al.  Leukocyte transmigration in inflamed liver: A role for endothelial cell-selective adhesion molecule. , 2009, Journal of hepatology.

[15]  C T Rubin,et al.  In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model. , 2009, Medical engineering & physics.

[16]  H. Kirikoshi,et al.  Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease , 2008, Gut.

[17]  R. McCuskey,et al.  Hepatic Microcirculation in Fatty Liver Disease , 2008, Anatomical record.

[18]  N. Musi,et al.  Diabetic eNOS knockout mice develop distinct macro- and microvascular complications , 2008, Laboratory Investigation.

[19]  山本 隆史.  摂食時の肝臓におけるSREBP-1c(Sterol Regulatory Element Binding Protein-1c)の転写制御メカニズムの解明 , 2007 .

[20]  P. Vollenweider,et al.  Endothelial Nitric Oxide Synthase (eNOS) Knockout Mice Have Defective Mitochondrial β-Oxidation , 2007, Diabetes.

[21]  J. Tuomilehto,et al.  Metabolic syndrome and cardiovascular disease , 2007, Annals of clinical biochemistry.

[22]  E. Clementi,et al.  Defective Mitochondrial Biogenesis: A Hallmark of the High Cardiovascular Risk in the Metabolic Syndrome? , 2007, Circulation research.

[23]  H. Aburatani,et al.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. , 2007, The Journal of clinical investigation.

[24]  P. Vollenweider,et al.  Endothelial nitric oxide synthase (eNOS) knockout mice have defective mitochondrial beta-oxidation. , 2007, Diabetes.

[25]  Sang Won Lee,et al.  Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. , 2006, Radiology.

[26]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[27]  R. McCuskey,et al.  Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice , 2004, Hepatology.

[28]  T. Saibara,et al.  Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. , 2004, Journal of hepatology.

[29]  B. Cha,et al.  Metabolic Syndrome and Cardiovascular Disease , 2003 .

[30]  D. Pessayre,et al.  Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug‐induced steatosis in mice , 2003, Hepatology.

[31]  P. Vollenweider,et al.  Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. , 2003, Swiss medical weekly.

[32]  E. Clementi,et al.  Mitochondrial Biogenesis in Mammals: The Role of Endogenous Nitric Oxide , 2003, Science.

[33]  Jing‐Yan Han,et al.  Regulatory mechanisms of hepatic microcirculation. , 2003, Clinical hemorheology and microcirculation.

[34]  Mitsuyo Okazaki,et al.  A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. , 2002, Journal of lipid research.

[35]  S. Todo,et al.  Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers. , 2002, Transplantation.

[36]  D. Pessayre,et al.  Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral‐related steatosis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  P. Vollenweider,et al.  Insulin Resistance, Hyperlipidemia, and Hypertension in Mice Lacking Endothelial Nitric Oxide Synthase , 2001, Circulation.

[38]  A. Seifalian,et al.  Hepatic Indocyanine Green Uptake and Excretion in a Rabbit Model of Steatosis , 2001, European Surgical Research.

[39]  S. Todo,et al.  Protective effect of agiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver. , 2001, Transplantation.

[40]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition. , 2001, The Biochemical journal.

[41]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[42]  M. Quon,et al.  Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. , 1996, The Journal of clinical investigation.